Hyderabad-based pharma company Biological E Limited (BE) has entered into an agreement with Janssen Pharmaceuticals for the development and manufacturing of Covid-19 drugs as well as Johnson &Johnson's (J&J) Covid-19 vaccine candidate.
The vaccine candidate is in phase 1/2a clinical trials.
Managing Director of Biological E, Mahima Datla said, "We are very pleased indeed to collaborate with an organisation like Johnson & Johnson. Given the magnitude of the Covid-19 pandemic, our ability to mount an effective response will be predicated on the ability to supply the vaccine globally and in significant quantities. This is best achieved through collaboration."
Biological E